Reconstruction of the superior vena cava: Benefits of postoperative surveillance and secondary endovascular interventions  by Alimi, Yves S. et al.
287
Obstruction of the superior vena cava (SVC) is
most frequently caused by primary or metastatic
mediastinal malignancies. Mediastinal fibrosis is the
most frequent cause of nonmalignant occlusion,
accounting for 10% to 20% of all patients who have
SVC syndrome.1,2 Central lines, indwelling
catheters, and pacemaker lines are additional causes
of thrombosis. Revascularization of the SVC can be
achieved by endovascular techniques3-19 or by sur-
gical reconstruction.20-32 Endovascular techniques
such as percutaneous transluminal angioplasty
(PTA) and stent placement with or without throm-
bolysis have been used preferentially for palliation
Reconstruction of the superior vena cava:
Benefits of postoperative surveillance and
secondary endovascular interventions
Yves S. Alimi, MD, Peter Gloviczki, MD, Terri J. Vrtiska, MD, Peter C.
Pairolero, MD, Linda G. Canton, RN, BSN, Thomas C. Bower, MD, W.
Scott Harmsen, MS, John W. Hallett, Jr., MD, Kenneth J. Cherry, Jr., MD,
and Anthony W. Stanson, MD, Rochester, Minn.
Purpose: Superior vena cava (SVC) reconstructions are rarely performed; therefore the
need for surveillance and the results of secondary interventions are unknown.
Methods: During a 14-year period 19 patients (11 male, 8 female; mean age 41.9 years,
range 8 to 69 years) underwent SVC reconstruction for symptomatic nonmalignant dis-
ease. Causes included mediastinal fibrosis (n = 12), indwelling foreign bodies (n = 4),
idiopathic thrombosis (n = 2), and antithrombin III deficiency (n = 1). Spiral saphenous
vein graft (n = 14), polytetrafluoroethylene (n = 4), or human allograft (n = 1) was
implanted.
Results: No early death or pulmonary embolism occurred. Four early graft stenoses or
thromboses (spiral saphenous vein graft, n = 2, polytetrafluoroethylene, n = 2) required
thrombectomy, with success in three. During a mean follow-up of 49.5 months (range,
4.7 to 137 months), 95 imaging studies were performed (average, five per patient;
range, one to 10 studies). Venography detected mild or moderate graft stenosis in seven
patients; two progressed to severe stenosis. Two additional grafts developed early into
severe stenosis. Four of 19 grafts occluded during follow-up (two polytetrafluoroethyl-
ene, two spiral saphenous vein graft). Computed tomography failed to identify stenosis
in two grafts, magnetic resonance imaging failed to confirm one stenosis and one graft
occlusion, and duplex scanning was inconclusive on graft patency in 10 patients. Angio-
plasty was performed in all four patients with severe stenosis, with simultaneous place-
ment of Wallstents in two. One of the Wallstents occluded at 9 months. Repeat percu-
taneous transluminal angioplasty was necessary in two patients, with placement of Pal-
maz stents in one. Only one graft occlusion and one severe graft stenosis occurred
beyond 1 year. The primary, primary-assisted, and secondary patency rates were 61%,
78%, and 83% at 1 year and 53%, 70%, and 74% at 5 years, respectively.
Conclusion: Long-term secondary patency rates justify SVC grafting for benign disease.
Postoperative surveillance with contrast venography is indicated in the first year to
detect graft problems. Endovascular techniques may salvage and improve the patency of
SVC grafts. (J Vasc Surg 1998;27:287-301.)
From the Division of Vascular Surgery, the Department of Diag-
nostic Radiology, and the Section of Biostatistics, Mayo Clinic.
Supported by a grant from A.DE.RE.M (Association pour le
développement des recherches biologiques et médicales au
Centre Hospitalier de Marseille, France) and by a grant (401-
131-9918/1027-96) from the Mayo Foundation.
Presented at the Fifty-first Annual Meeting of The Society for
Vascular Surgery, Boston, Mass., June 1–4, 1997.
Reprint requests: Peter Gloviczki, MD, Mayo Clinic, 200 First St.
SW, Rochester, MN 55905.
Copyright © 1998 by The Society for Vascular Surgery and Inter-
national Society for Cardiovascular Surgery, North American
Chapter.
0741-5214/98/$5.00 + 0 24/6/86060
of symptoms in malignant disease.12,17 However,
primary venous stenting has been performed with
increasing frequency in patients with benign SVC
syndrome.7,8,10,11,15,16,19 At our institution surgical
treatment has been used since the mid-1980s to
treat patients with symptomatic SVC syn-
drome.25,28,29,31,32 In some of these patients
endovascular techniques have been used as sec-
ondary interventions to salvage failing SVC grafts.
This report evaluates the late outcome of surgical
reconstructions in SVC syndrome caused by benign
disease and focuses on the benefits of postoperative
surveillance and secondary endovascular interven-
tions in maintaining graft patency.
METHODS
Between November 1, 1983, and December 31,
1996, 19 consecutive patients underwent surgical
reconstruction for SVC syndrome caused by nonma-
lignant disease (Table I). Eleven men and eight
women with a mean age of 41.9 years (range, 8 to
69 years) were evaluated. All had persistent signs and
symptoms of SVC obstruction (mean, 22 months;
range, 4 to 72 months) despite medical treatment
and physical measures to decrease venous conges-
tion of the head and neck (Table II). The most fre-
quent signs of SVC syndrome were head or neck
swelling (100%) and the presence of visible large
chest-wall collateral veins (89%). The most frequent
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Fig. 1. A, Type I: high-grade superior vena cava stenosis but still normal direction of blood
flow through superior vena cava and azygos veins. Increased collateral circulation through
hemiazygos and accessory hemiazygos veins. B, Type II: greater than 90% stenosis or occlu-
sion of superior vena cava with normal direction of blood flow through the azygos vein. 
symptoms included a feeling of fullness in the head
or neck (74%), dyspnea on exertion or orthopnea
(63%), and cough (32%).
The most frequent cause (Table I) of SVC syn-
drome was mediastinal fibrosis in 12 patients (63%)
and a history of histoplasmosis in four. Indwelling
foreign bodies (Hickman catheter, pacemaker wire,
central line placement, and ventriculoatrial shunt)
caused SVC thrombosis in four patients (21%). One
patient had an attempted SVC replacement at
another institution after early thrombosis of a Wall-
stent occurred. Another patient had a Palmaz stent
placement for a type III lesion (Table III) in anoth-
er hospital that resulted in early recurrent symptoms
and thrombosis, and the patient was transferred to
our institution for surgical reconstruction.
Preoperative imaging, in addition to biplane
chest roentgenography, included bilateral upper
extremity venography in 19 patients (100%) and
duplex scanning of the internal jugular veins in 12
(63%). Seventeen patients (89%) underwent comput-
ed tomography (CT) of the chest, four (21%) under-
went magnetic resonance imaging, and four (21%)
underwent echocardiography. Five patients under-
went mediastinoscopy before SVC reconstruction.
With the classification scheme of Stanford and
Doty,33 on the basis of the severity of SVC occlusion
and the extent of collateral venous circulation, our
patients were classified into four types (Table III,
Fig. 1).
The technique of autologous spiral saphenous
vein graft has been described in detail previous-
ly.28,31 In brief, the saphenous vein is removed and
opened longitudinally. We excise the valves and wrap
the saphenous vein around a 32F or 36F polyethyl-
ene chest tube. The spiral vein graft is prepared by
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Fig. 1. C, Type III: occlusion of superior vena cava with
retrograde flow in both azygos and hemiazygos veins. 
Fig. 1. D, Type IV: extensive occlusion of superior vena
cava, innominate and azygos with chest wall and epigastric
venous collaterals. 
suturing the edges of the saphenous vein with run-
ning 6.0 or 7.0 monofilament nonabsorbable
sutures. Harvesting vein from the groin to the knee
will result in an approximately 10 cm long spiral
saphenous vein graft.
Reconstruction with autologous spiral saphe-
nous vein graft (SSVG) was performed in 14 patients
(74%); 12 had straight SSVGs, and two had bifur-
cated grafts. Of the straight grafts, the site of the
proximal anastomosis was the internal jugular vein in
five patients and the innominate vein in seven. In
one patient (case 16) the left innominate vein was
reimplanted into a right innominate vein. One limb
of each of the two bifurcated grafts originated from
the internal jugular vein, and the other originated
from the innominate vein. The site of the central
anastomosis was the right atrial appendage in 10
patients (71%) and the SVC in four (29%).
Four patients received an externally supported
expanded polytetrafluoroethylene (ePTFE) graft,
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Table I. Clinical data of 19 patients with superior vena cava syndrome caused by nonmalignant disease
Patient Age Cause Location of graft Type of graft Early graft 
no. (yr)/ sex complications
1 36/M Ventriculoatrial shunt Left-IJV-RAA SSVG —
2 56/M Pacemaker electrode Right IVJ-RAA SSVG —
3 43/F Mediastinal fibrosis* Right IJV-left SSVG Graft 
IV-RAA thrombosis† 
(partial)
4 27/M Mediastinal fibrosis* Left IV-RAA SSVG —
5 69/M Pacemaker electrode Right IJV-RAA SSVG —
6 8/M Antithrombin III deficiency IV-RAA PTFE Graft thrombosis†
7 46/F Idiopathic venous thrombosis Right IJV-RAA PTFE Graft thrombosis†
8 30/F Mediastinal fibrosis* Left IV-RAA SSVG —
9 41/F Mediastinal fibrosis* Left IV-RAA Human allograft —
10 65/F Mediastinal fibrosis* Left IV-RAA SSVG —
11 44/M Mediastinal fibrosis* Left IJV-RAA SSVG —
12 36/M Mediastinal fibrosis* Left IV-RAA SSVG —
13 37/F Central line placement Left IJV-RAA SSVG —
no-
14 46/M Idiopathic venous thrombosis Right IVJ-RAA PTFE —
15 40/M Mediastinal fibrosis* Left IV-right SSVG Graft thrombosis†
IJV-SVC
16 24/M Mediastinal fibrosis* Right IV-left SSVG —
IV-SVC
17 45/M Mediastinal fibrosis* IV-SVC SSVG —
18 60/F Mediastinal fibrosis* Right IV-SVC SSVG —
19 44/F Mediastinal fibrosis* Left IV-RAA PTFE —
IJV, Internal jugular vein; RAA, right atrial appendage; IV, innominate vein; D scan, Duplex scanning; MRA, magnetic resonance 
angiography; SSVG, spiral saphenous vein; PTFE, externally supported expanded polytetrafluoroethylene.
*History of histoplasmosis.
†Thrombectomy with revision.
‡Scoring system suggested by the Subcommittee of the Joint Vascular Societies on Reporting Standards in Venous 
Disease35: +3 = complete relief of symptoms, +2 = marked relief of the symptoms, +1 = mild clinical improvement, 0 = no clinical 
improvement.
two originating from the internal jugular vein and
two from the innominate vein. The central anasto-
moses was performed with the atrial appendage in all
four patients.
One additional patient with severe symptoms of
SVC who had concomitant orthotopic liver trans-
plantation received a human iliocaval allograft
implanted from the left innominate vein to the right
atrial appendage. This patient was reported recently.32
The Kaplan-Meier method was used to calculate
primary, primary-assisted, and secondary graft
patency rates.34
All except two patients were receiving oral anti-
coagulation at discharge. Low molecular weight
heparin was used in one patient, and dipyridamole
was given to the remaining patients to decrease
thrombotic complications.
RESULTS
No early deaths or pulmonary thromboem-
bolism occurred. Four early reinterventions were
necessary for stenosis in one patient and for occlu-
sion in three. The stenosis occurred in a bifurcated
SSVG; the occlusions occurred in one limb of a
bifurcated SSVG and in two PTFE grafts. A fifth
patient required reoperation for evacuation of a
mediastinal hematoma. The 30-day primary patency
rate was 79% (15 of 19), and the secondary patency
rate was 95% (18 of 19). One limb of a bifurcated
SSVG graft reoccluded.
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Patency at Late Endovascular Last Graft patency Clinical out
discharge complications treatment imaging documented by come score‡
imaging
Patent — Venogram Patent at 5 mo +2 at 5 mo, 
lost to follow-up
Patent — CT scan Patent at 72 mo +3 at 96 mo
Patent 3 restenoses PTA (· 3) Venogram Right limb not  +2 at 95 mo
(at 37, 51 and visualized by
71 mo) CT at 3 mo; 
both (!) limbs
Patent at 72 mo
Patent — — Venogram Patent at 73 mo +3 at 88 mo
Patent — — Duplex scan Patent at 65 mo +3 at 84 mo
Patent — — MRA Patent at 23 mo +2 at 24 mo, 
lost to follow-up
Patent — — Duplex scan Occluded at 5 mo 0 at 37 mo
Patent — — MRA Patent at 52 mo +2 at 52 mo
Patent — — Duplex scan Patent at 22 mo +3 at 28 mo
Patent — — Venogram Patent at 17 mo +3 at 18 mo
Patent 3 restenoses
(at 3, 5, and 6 mo) PTA at 3 mo, Venogram Patent at 14 mo +2 at 20 mo
PTA with Palmaz 
stents at 5 and 6 mo
Patent 1 restenosis Treated with Venogram Patent at 17 mo +3 at 17 mo
(at 10 mo) PTA+Wallstent
Patent — — Venogram Patent at 109 mo +2 at 109 mo
Death (bron-
chogenic carci-
ma)
Patent — — CT scan Patent at 57 mo +3 at 137 mo
1 limb occluded — — CT scan 1 limb patent +1 at 8 mo
at 4 mo, 1 limb 
occluded
Patent 1 restenosis Treated with Venogram Occluded at 9 mo +1 at 9 mo
(at 5 mo) PTA+Wallstent
Patent — — Venogram Patent at 49 mo +3 at 59 mo
Patent — — Venogram Patent after surgery +3 at 45 mo
Patent — — Venogram Occluded at 26 mo +2 at 26 mo
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Fig. 2. A, Postoperative venogram of 43-year-old woman after bifurcated spiral saphenous
vein graft implantation reveals bilateral stenosis (arrows) in limbs of bifurcated graft. B,
Venogram at 37 months reveals widely patent limbs of bifurcated graft. Lysis of thrombus in
graft occurred while patient was receiving oral anticoagulation. C, Percutaneous transluminal
angioplasty of stenosis at the atrial anastomosis. D, Venogram confirmed successful angioplas-
ty of anastomotic stenosis with no residual gradient.
During a mean follow-up of 49.5 months (range,
4.7 to 137 months), one late death occurred as a
result of bronchogenic carcinoma at 9 years in a
female patient who had a patent SSVG and no symp-
toms of SVC syndrome at the time of her death (case
13). Three patients were lost to follow-up at 5, 8,
and 24 months, respectively (Table I). The median
follow-up for the last imaging studies was 23
months, whereas the median follow-up of clinical
outcome was 37 months.
The late clinical outcome was assessed with a
classification scheme suggested by the Subcommit-
tee of the Joint Vascular Societies on Reporting
Standards in Venous Disease.35 Complete relief of
symptoms (+3) was obtained in nine patients (46%),
marked relief (+2) in seven (33%), only mild clinical
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Fig. 3. A, Venogram 6 months after placement of left
innominate vein atrial appendage spiral saphenous vein
graft in 46-year-old man revealed mild stenosis at proximal
anastomosis (arrow indicates stenosis). B, Venogram at 10
months reveals severe stenosis at proximal anastomosis.
Note presence of mediastinal collaterals (arrowhead) indi-
cating partial obstruction of flow in graft. C, Venogram 6
months after Wallstent placement confirms widely patent
stent and graft. 
improvement (+1) in two (11%), and no clinical
improvement in one (5%). Worsening of symptoms
was not noted in any of the patients. The patient
who did not have any clinical improvement was
found to have graft thrombosis at 5 months.
Postoperative imaging confirmed nonsignificant
(<50%) stenosis in seven patients, six within the first
year. In three patients stenosis was noted before hos-
pital dismissal, in two at the first postoperative visit,
and in the last at 34 months. Two of these patients
progressed to severe stenosis, requiring endovascular
treatment at 3 months and 37 months after surgery
(cases 3 and 11; Table I). Two additional patients
had severe stenosis. All four patients with severe
stenosis had recurrent symptoms at the time of pre-
sentation. Three stenoses developed within 1 year
after surgery (at 3, 5, and 10 months, respectively),
and the fourth patient had severe recurrent stenosis
at 37 months. This patient (case 3) underwent early
thrombectomy for high-grade stenosis caused by
thrombus deposition throughout the entire graft.
The patient was discharged with mild graft stenosis,
and at 3 months the right limb of the bifurcated
graft could not be seen with CT scan. Oral antico-
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Fig. 4. A, Venogram at 5 months in 24-year-old man
reveals severe stenosis (arrow) in right innominate vein
superior vena cava spiral saphenous vein graft. Left innom-
inate vein was reimplanted into saphenous vein graft. B,
Venogram after placement of Wallstent (10 · 60 mm)
shows good flow through the graft. C, Venogram at 9
months confirms occluded graft and stent.
agulation was maintained, and both limbs of this
bifurcated SSVG were widely patent on venography
at 37 months. However, recurrent stenosis at the
atrial anastomosis required balloon angioplasty. The
incidence of early and late stenosis in our total expe-
rience was 37% (7 of 19).
All four patients with high-grade stenosis under-
went PTA, stenting, or both. Recurrent stenosis in
case 3 was initially treated first with PTA at 37
months. Repeat PTAs were performed at 51 and 71
months because of recurrent symptoms. This patient
currently has minimal residual symptoms at 95
months after surgery (Fig. 2).
PTA performed at 3 months for early restenosis
was not successful in a 44-year-old man with SSVG
to prevent recurrence of symptoms (case 11). PTAs
with placement of Palmaz stents (Johnson and John-
son Interventional Systems) at 5 and 6 months at
the referring hospital were successful, with patent
graft documented at 14 months and significant clin-
ical improvement documented at 20 months.
A third patient with symptomatic stenosis of a
straight SSVG at 10 months (case 12) was treated
with PTA and placement of a Wallstent. Venogra-
phy at 17 months revealed no pressure gradient
and a widely patent graft (Fig. 3) with excellent
clinical result. The fourth patient with an SSVG
had high-grade stenosis at 5 months after surgery.
This SSVG had the left innominate vein implanted
into the side of a right innominate vein–SVC graft,
and revisions for kinking were performed during
initial implantation. Treatment was attempted with
PTA and placement of a 10 mm self-expanding
metallic stent (Wallstent, Medivent). The pressure
gradient of 26 mm Hg was decreased to a residual
gradient of 16 mm Hg. Reocclusion with recur-
rence of symptoms was documented at 9 months
after surgery (Fig. 4). After stent placement all
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Fig. 5. Cumulative patency rates of 19 bypass grafts used for superior vena cava reconstruction.
Fig. 6. Cumulative patency rates of 12 straight spiral saphenous vein grafts used for superior
vena cava reconstruction.
patients underwent full anticoagulation with
heparin and then with warfarin.
Three additional graft occlusions occurred dur-
ing follow-up. One was the early reocclusion of one
limb of a bifurcated SSVG (case 15). Another
patient with extensive type IV SVC syndrome (case
7) had occlusion of a jugular vein-atrial appendage
PTFE graft. Because of the extensive occlusive dis-
ease and small jugular vein, a 6-mm graft had to be
used in this patient. After successful early thrombec-
tomy was performed, the graft reoccluded at 5
months. Another 10 mm PTFE graft occluded at 26
months after surgery (case 19).
The long-term secondary patency rate was 100%
(three of three) in patients with type I disease, 67%
(two of three and four of six, respectively) in patients
with types II and III, and 85% (six of seven) in
patients with type IV disease. Primary, primary-assist-
ed, and secondary patency rates of all grafts were
61%, 78%, and 83% at 1 year and 53%, 70%, and 74%
at 5 years, respectively (Fig. 5). Straight SSVGs had a
70% primary patency rate and a 90% secondary
patency rate at both 1 and at 5 years (Fig. 6).
During follow-up of the 19 patients, 95 imaging
studies were performed, averaging five per patient
(range, 1 to 10). Forty-five venograms were
obtained and documented mild or moderate steno-
sis in eight studies (seven patients) and severe graft
stenosis in eight grafts or limbs (four patients). Of
the noninvasive examinations, 22 CT scans, three
magnetic resonance imaging examinations, and 19
postoperative duplex scan examinations were per-
formed. CT failed to identify graft stenosis in two of
seven cases and was inconclusive in one. Magnetic
resonance imaging failed in two out of two cases
(one stenosis, one occlusion), and duplex scanning
was inconclusive on graft patency in 10. In none of
the patients could duplex scanning visualize the graft
in the mediastinum. Patency of the internal jugular
veins with good flow velocities and associated respi-
ratory variations were indirect evidence of graft
patency.
DISCUSSION
Surgical treatment of SVC syndrome has docu-
mented long-term success in both benign and malig-
nant disease.20-32 Of the available autologous mate-
rial, SSVG has been used most frequently for bypass
grafting.20,24,25,28 Advantages of SSVG are that it is
autologous material and that graft diameter can be
matched to the size of the internal jugular or innom-
inate veins. Potential disadvantages include the time
needed to prepare the graft (45 to 90 minutes), lim-
itations in lengths, and that endothelial injury dur-
ing preparation may increase thrombogenicity. We
had early thrombosis in two bifurcated SSVGs, and
thrombectomy with revision failed to salvage one
limb in one graft. Severe symptomatic stenosis
developed within the first few months in three
SSVGs and at 37 months in another. Patency of
three grafts could be salvaged by endovascular tech-
niques. Our study confirmed that straight SSVGs
have excellent long-term patency rates, with 11 of
12 grafts patent during an average follow-up of 50
months. The only occluded straight SSVG required
revision immediately after placement because of
kinking caused by reimplantation of the left innom-
inate vein into the graft. Subsequent placement of a
10 mm Palmaz stent in the stenotic graft failed to
maintain patency.
Good long-term results with SSVG used for
treatment of patients with nonmalignant SVC syn-
drome were also reported by Doty.20 In a group of
nine patients, seven with mediastinal fibrosis, two
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Table II. Signs and symptoms of SVC syndrome in
19 patients with benign disease
Signs No. of %
patients
Head and neck swelling 19 100
Large chest wall venous collaterals 17 89
Arm swelling 11 58
Facial cyanosis 8 42
Symptoms
Feeling of fullness in head or neck 14 74
Dyspnea on exertion or orthopnea 12 63
Headaches 7 37
Visual problems, painful eyes 5 26
Cough 6 32
Table III. Venographic classification of 19 patients
with SVC syndrome according to Stanford and
Doty33
Type No. of %
patients
I. Stenosis (<90%) of SVC with patency 3 16
and antegrade flow of azygos-right 
atrial pathway
II. >90% stenosis or occlusion of SVC 3 16
with patency and antegrade flow in 
azygos-right atrial path
III. >90% stenosis or occlusion of SVC 6 32
with reversal of azygos blood flow
IV. Occlusion of SVC and one or more 7 37
major caval tributary including 
azygos systems
Total 19 100
graft occlusions were noted at 5 and 12 months after
surgery. Seven of nine patients had excellent clinical
results at a mean follow-up of 82 months. These
results support our policy to continue to use SSVG
as the graft of choice in these patients. However,
increasing success with superficial femoral vein as an
arterial conduit has resurrected this autologous graft
for large vein reconstructions as well. Recent reports
on good early results indicate that when available,
autologous femoropopliteal vein shows promise for
replacement of large central veins.36 Still, the mor-
bidity of harvesting a deep vein in patients with
thrombotic potentials and venous thrombosis else-
where in the body is not well known.
Early failure of grafts implanted in the venous
system can be caused by technical failure resulting
in stenosis of the graft at the anastomosis or extrin-
sic compression by the thoracic inlet or the ster-
num. Low flow may also result in early thrombosis
of prosthetic grafts. Intimal hyperplasia and recur-
rent venous thrombosis have been causes of late
graft failure. Therefore in patients who have antico-
agulation abnormalities, lifelong anticoagulation is
warranted.
Of the available prosthetic materials, externally
supported expanded PTFE continues to be the best
conduit. Grafts with less than 10 mm internal diam-
eter, however, have poor patency rates because low
flow results in thrombus deposition on the throm-
bogenic surface of a prosthesis. One of our two
occluded prosthetic grafts was 6 mm in diameter.
Moore and Hollier27 reported six patients with non-
malignant central vein occlusion treated with PTFE
grafts. Five of these patients, however, had brachial
arteriovenous fistula placed to improve flow through
the prosthetic grafts, indicating that high flow is
required to keep prosthetic grafts patent in the
venous system. All grafts had documented patency at
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Table IV. Endovascular treatment of nonmalignant SVC syndrome
First  No. of Sex/age Cause Type of Treatment Patency at Clinical 
author patients (yr) lesion* last imaging outcome 
(yr) score†
Sunder11 (1992) 1 F/68 Pacing electrode IV Lysis (UK)+PTA ? +3 ( 12 mo)
Sherry4 (1986) 1 F/82 Pacing electrode I PTA Restenosis +3 after 
at 15 mo repeated 
PTA
Grace8 (1991) 1 F/53 Pacing electrode I PTA ? +3 (6 mo)
Lindsay15 (1994) 1 M/63 Pacing electrode III Lysis+PTA+Wall- Thrombus +3 (6 mo)
stent (16 mm) in stent at 
6 mo.
Dodds2 (1994) 1 M/44 Mediastinal fibrosis II PTA+Palmaz stents Patent after +3 (8 mo)
(12&15 mm) thrombolysis 
at 8 mo
Kastner18 (1995) 1 M/45 Pacing electrode I PTA Patent at +2 (6 mo)
6 mo
Walpole6 (1988) 1 M/71 Pacing electrode II PTA Patent at +2 (9 mo)
9 mo
Frances16 (1995) 1 M/70 Pacing electrode III TA+Wallstent Patent at +3 (6 mo)
16 mm 6 mo
Rösch12 (1992) 2 F/58 Postradiation fibrosis III Gianturco-Rösch Mild  +3 (11 mo, 
self-expandable stenosis death of 
Z-stents at 2 mo unrelated 
cause)
? Mediastinal fibrosis II Gianturco-Rösch ? +3 (12 mo)
self-expandable 
Z-stents
Dondelinger19 20 ? Central venous ? PTA + Wallstent 1 failure; 6  Primary 
(1996) catheter, 16; or Gianturco redo PTA patency 
mediastinal fibrosis, stent with stents rate, 72%
1; idiopathic 
thrombosis, 3
*See Table III.
†Scoring system suggested by the Subcommittee of the Joint Vascular Societies on Reporting Standards in Venous Disease35: +3 = com-
plete relief of symptoms, +2 = marked relief of symptoms.
1 year, and all patients had excellent clinical results
at a mean follow-up of 30 months.
Our data indicate that contrast venography is the
most reliable study to document stenosis in central
vein grafts, and duplex scanning will only provide
indirect evidence of patency. Contrast venography
has been performed in all patients before discharge
and is recommended again at 3 to 6 months for
postoperative surveillance even in patients who have
no symptoms. We have to admit, however, that cur-
rently available data do not support the use of rou-
tine venography in all patients. Most problems
occurred in our study within the first year, and two
patients with mild to moderate stenosis progressed
to severe stenosis. Follow-up venography in patients
with documented stenosis is warranted even after 1
year. It is noteworthy, however, that all patients with
severe stenosis had recurrent symptoms, and of the
three late occlusions only one patient had no warn-
ing symptoms before occlusion. In patients with
renal insufficiency, magnetic resonance angiography
has become our second choice. Our experience is
accumulating with magnetic resonance angiography
with gadolinium enhancement, but artifacts from
pacemakers in many of these patients make follow-
up with this examination problematic.
Consideration of endovascular therapy as an
adjunctive measure to improve results of surgical
SVC reconstruction is important. In our series
endovascular therapy was useful in a small group of
patients; however, it resulted in increased patency
rates and symptomatic improvement in three of four
patients treated. All four patients who had sympto-
matic severe stenosis during follow-up underwent
PTA, and three had stent placement.
Three basic stent types have been used most fre-
quently for treatment of SVC syndrome: the
Gianturco Z stents (with the Rosch-modification),
the Wallstent, and the Palmaz stent. Advantages of
the Z stent are that it can be custom-built to appro-
priate length and it is available in larger sizes (16
mm and greater), which makes it more conducive
for the treatment of patients with central vein
obstruction. However, stent migration has occurred
with Gianturco Z stents, especially with the uni-
body design. Rösch et al.12 successfully added small
barbs and used multibody design to prevent stent
migration.
Wallstents have been used successfully to treat
patients with SVC obstruction.16 The 16 mm or
larger diameter stents have only become recently
available in the United States. The advantage of this
stent is its flexibility, and in our patient it allowed
placement along the curved extent of an SSVG. The
disadvantage of the Wallstent is the decreased expan-
sile force compared with Z stents or Palmaz stents.
Palmaz stents are widely used in the arterial bed,
but their use for SVC syndrome has also been
reported.2,9 The advantage of the Palmaz stent is the
precision with which it can be placed and the ability
to increase the diameter as needed at deployment.
Its disadvantage is the lack of flexibility.
In patients with malignant disease short-term pal-
liation is the goal, and endovascular techniques have
been quite successful. In nonmalignant SVC syn-
drome, however, reconstruction with reliable long-
term patency is required. Currently available literature
on endovascular techniques in this group of patients
is limited to case reports or small series (Table IV),
and results on patency beyond 1 year have usually not
been reported. Recently presented data of Don-
delinger and Trotteur,19 however, are promising,
because these authors performed stenting in 26
patients with large vein occlusion caused by benign
disease and in 20 with SVC syndrome. The secondary
patency rate in the entire group was 80% after a mean
follow-up of 16 months. Although additional data are
needed, the observations of these authors support the
preferential use of stenting in patients with types I and
II SVC obstruction caused by benign disease. Prima-
ry surgical treatment in our experience should be
offered to all patients with more extensive benign
SVC occlusion (types III and IV) or if endovascular
attempts fail in less severe disease.
CONCLUSION
Long-term secondary patency rates justify SVC
grafting for benign disease. In our experience
straight SSVGs have performed the best and contin-
ue to be our graft of choice for this operation. Post-
operative surveillance and contrast venography
before discharge and again at 3 to 6 months is indi-
cated to detect graft stenosis. Beyond the first year
patients should undergo contrast venography when
symptoms develop. Endovascular techniques with
PTA and stenting are useful, and they can salvage
and improve the patency of SVC grafts.
We thank Duane M. Ilstrup, MS, for his advice and
statistical analysis of the data and Marcia Simonson for her
editorial assistance.
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spiral vein grafts compared with PTFE grafts, and how
would you compare that with the endovascular tech-
niques?
Dr. Yves S. Alimi. Thank you, Dr. Hollier, for your
thoughtful comments. Your expertise in this field is well
recognized. I have the following answers for your ques-
tions.
In patients with malignant disease, short-term pallia-
tion is the goal and endovascular technique has been quite
successful. In nonmalignant superior vena cava syndrome,
however, reconstruction with reliable long-term patency is
required. Currently available literature on endovascular
procedures in this group of patients is limited to case
reports of small series, and results on patency beyond 1
year have usually not been reported.
We saw recently the data of Dondelinger, however,
which are promising because his group performed stent-
ing in 26 patients with large vein occlusion caused by
benign disease including 20 patients with superior vena
cava syndrome. The secondary patency rate in the entire
group was 80% after a mean follow-up of 16 months. Also,
additional data are needed. Observations of this author
support a preferential use of stenting in patients with type
I and II benign disease.
Concerning the question on dialysis, we had no
patient on dialysis during reconstruction, so this series is a
little bit different than the one you published.
The third question was about the benefit of spiral
saphenous vein graft. In our point of view, spiral saphe-
nous vein graft has definite advantages; it is autologous
material, and the graft diameter can be matched to the size
of the internal jugular or innominate vein. Potential dis-
advantages include the time needed to prepare the graft,
limitation in length, and that endothelial injury may occur
during preparation, which may increase thrombogenicity.
In our series we had the best results with spiral saphenous
vein graft, and it remains our first choice.
Dr. Jorg D. Gruss (Kassel, Germany). I enjoyed your
paper very much and want to point out that there is a very
elegant extraanatomic alternative treatment for decom-
pressing the superior caval vein. We just implant the
greater saphenous vein into the infraclavicular subclavian
vein. If necessary, we can do this on both sides. The results
of this simple procedure are convincing because of the
high pressure gradient. Thank you.
Dr. G. Patrick Clagett (Dallas, Tex.). I rise to point
out that there is an alternative vein graft and that is the
superficial femoral vein. It is a large caliber vein that is
readily available, straightforward to harvest, and associat-
ed with minimal venous morbidity. We have used this in
two patients with SVC syndrome, one for malignant and
one for benign disease, with a follow-up of 3 years and 1
year. They are both widely patent, and it seems to be an
excellent choice for this problem.
Dr. Laurens R. Pickard (Houston, Tex.). You men-
JOURNAL OF VASCULAR SURGERY
300 Alimi et al. February 1998
Dr. Larry H. Hollier (New York, N.Y.). First of all, I
would like to congratulate Dr. Alimi on a very nice pre-
sentation. Dr. Gloviczki and his colleagues at Mayo Clinic
are also to be congratulated for a superb article.
The large patient volume that Mayo Clinic has and
their excellent ability to provide long-term follow-up has
provided us with some very valuable data demonstrating
the efficacy of superior vena caval reconstruction. As many
of you recall, for many years we went under the assump-
tion that major central venous reconstruction had very lit-
tle value and had a very high failure rate. I think most of
us now are quite convinced that superior vena caval recon-
struction does have a very valuable role to play in treating
patients who have quite disabling symptoms.
I was interested to see that they used so many spiral
vein grafts in the reconstruction of these obstructions. It
has been my impression for a long time that the external
supported PTFE grafts had a distinct advantage in these
central venous reconstructions. I noticed also that you did
not include the data on patients with malignant disease,
where we have included that as we reviewed these studies
and found there that very clearly external support was of
some added value.
In a previous study performed by myself and some of
my cardiology colleagues, Chris White and Steve Ramey
and others, we compared the central venous reconstruc-
tions with primary endovascular procedures. And looking
at the 1-year patency rate of the surgical reconstructions,
we had approximately an 87% primary patency rate. If we
looked at the 1-year patency rate of the balloon angioplas-
ty patients, that was down to approximately 35%. Howev-
er, when we looked at the patients for long-term com-
bined patency, both secondary and assisted patency, we
found that out to 2 years the patency rate in both groups
was still in the mid-80% range and that surgical recon-
struction did not add any additional increase in patency
compared with those patients treated with endovascular
procedures alone if you allowed secondary balloon angio-
plasty or stenting in these patients.
So my first question to the authors is how frequently
are you using endovascular procedures as the primary
treatment of central venous obstruction? And of those in
whom you have done primary endovascular procedures,
what has been the patency rate of those patients?
Another question is that most of the rapid develop-
ment of symptoms of central venous obstruction we have
seen has been related to patients receiving chronic
hemodialysis with an atrioventricular access in the same
arm where you might have an innominate obstruction.
How many of your patients were undergoing chronic dial-
ysis during these times of reconstruction, and how many
of the stenoses were related specifically to catheter-
induced obstruction in patients receiving chronic dialysis?
Again, the final question I would ask specifically is do
you still believe that there is an added value for the use of
DISCUSSION
tioned one of your patients who required repeated balloon
angioplasty successfully, and it made me wonder if you
have a policy now on when you go to a stent after an ini-
tial balloon angioplasty for stenosis, why you would have
repeated balloons without a stent?
Dr. Alimi. We use stents selectively in patients with an
extrinsic compression of central veins or in those with
recurrent stenosis after the first PTA. We always measure
pressure above and below the stenosis. If the pressure gra-
dient is still high after the PTA, most patients undergo
stent placement.
Dr. Peter Gloviczki (Rochester, Minn.).Just one addi-
tional comment to the site and the choice of the stent. If
the stenosis is within the graft, then we would certainly
prefer angioplasty and stenting. If it is right in the right
atrial appendage or at that anastomosis, our radiologist
may be a little bit reluctant to place a stent because of fail-
ure of distal displacement of the stent.
And the other comment that I would like to make is
that we have shifted a little bit during the last decade, and
certainly in type I and type II lesions where there is only a
short segment of stenosis, we too perform primary stent-
ing and that is our first choice. But most of the patients
who undergo reconstruction now are either failure of pre-
vious stent placement or they have extensive venous occlu-
sion that is chronic and not suitable for thrombolysis or
stenting.
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